[Previous Months][Date Index][Thread Index][Join - Register][Login]   Help@Insulin-Pumpers.org
  [Message Prev][Message Next][Thread Prev][Thread Next]   for subscribe/unsubscribe assistance

RE: [IPk] Humalog


I will send you off-list a PDF of a journal article that shows LOWER 
mitogenic potency among rapid-acting insulin analogues vs. regular 'human' 
rDNA insulin (Actrapid, Humulin R). Mitogenic potency is the fancy term for 
'if you put this stuff in a Petri dish with cells, what's the chance they'll 
grow fast?' Uncontrolled cell growth is, of course, the origin of a tumour.

I am confident using Humalog in my pump, knowing that the mitogenic potency 
is much lower than that of Human R. However, there is NO DIRECT EVIDENCE 
(want to be clear!!!) that ANY insulin currently marketed causes tumours in 
humans. The very first insulin analogue product developed by Novo Nordisk 
did cause tumours in animal studies and it was thus very swiftly abandoned 
and has never been sold. Its mitogenic potency was more than 10 times 
greater than human R.

The mitogenic potency of Lantus (insulin glargine) is nearly 8 times greater 
than the mitogenic potency of human R, though, and this has raised some 
eyebrows in the scientific community. We know that Lantus doesn't cause 
tumours in animals over their few-year lifespan (valuable information) but 
we don't know yet what happens in humans over a 20-odd-year span. The 
benefits of Lantus in terms of clinical data with regard to diabetes control 
outweighed the risks of "the unknown" in the regulatory bodies' evaluations. 
If we want drugs that may give us a better quality of life *now*, we can't 
hold them in clinical trials for 25 years...life is full of risk/benefit 
equations, isn't it?

Type 1 13 years; MiniMed pumper 7.5 years; Animas pumper 2.5 years; nary a 
molecule of intermediate- or long-acting insulin in 10 years!!
for HELP or to subscribe/unsubscribe/change list versions,
contact: HELP@insulin-pumpers.org